Neoadjuvant intraperitoneal and systemic chemotherapy combined with sintilimab conversion therapy for peritoneal metastasis of gastric cancer:a report of 2 cases
Yang Lebin
Shan Hanguo
Yang Fan
Peng Su
Chen Maoliang
Wang Chunyun
Abstract：Peritoneal metastasis in advanced gastric cancer is the most common form of distant metastasis in patients with poor prognosis.Neoadjuvant intraperitoneal combined with systemic chemotherapy(NIPS)and immunotherapy represented by programmed cell death protein 1 inhibitors have been gradually applied to the treatment of peritoneal metastasis of gastric cancer.In this study,two patients with advanced gastric cancer with peritoneal metastasis were reported.Laparoscopic exploration indicated peritoneal metastasis,and they were treated with oxaliplatin and tegafur,gimeracil and oteracil potassium combined with albumin-bound paclitaxel systemic and intraperitoneal chemotherapy,and sintilimab intravenous infusion for 4 cycles.After conversion therapy,the patient's imaging showed partial remission,and then laparoscopic exploration was performed,and no clear peritoneal metastasis was found in the exploration.The radical resection was successfully performed,and the postoperative pathology showed effective downstaging,and the patient recovered smoothly.The results indicate that NIPS combined with sintilimab is effective and safe in the conversion therapy of gastric cancer with peritoneal metastasis,but this mode needs more research to prove.
Keywords：Gastric cancerPeritoneal metastasisNeoadjuvant intraperitoneal combined with systemic chemotherapyImmunotherapyTransformation therapy
Publication Date：2024-12-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1865-1868 )